An increase in the serum concentration of pancreatic enzymes (amylase and lipase) was reported in a proportion of imatinib-resistant and/or intolerant Philadelphia-positive chronic myeloid leukemia patients treated with nilotinib. Acute pancreatitis was very rare, and the relevance of these laboratory alterations remains unknown. We report on 8 chronic myeloid leukemia patients who developed serum lipase/amylase elevation during treatment with nilotinib. After a median follow-up of 26 months, none of these patients developed an acute pancreatitis or clinical signs of pancreatic disease. Pancreatic hyperenzymemia never led to permanent drug discontinuation and required nilotinib temporary interruption in one case only. The median cumulative duration of dose interruptions and response to treatment were comparable in patients with or without pancreatic enzyme elevation. The mechanisms of action of nilotinib on pancreatic enzymes deserves to be investigated: however, in our experience, the relevance of pancreatic hyperenzymemia was clinically very limited.

Palandri F, Castagnetti F, Soverini S, Poerio A, Gugliotta G, Luatti S, et al. (2009). Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. HAEMATOLOGICA, 94(12), 1758-1761 [10.3324/haematol.2009.010496 ].

Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure

PALANDRI, FRANCESCA;CASTAGNETTI, FAUSTO;SOVERINI, SIMONA;POERIO, ANGELA;GUGLIOTTA, GABRIELE;LUATTI, SIMONA;AMABILE, MARILINA;MARTINELLI, GIOVANNI;ROSTI, GIANANTONIO;BACCARANI, MICHELE
2009

Abstract

An increase in the serum concentration of pancreatic enzymes (amylase and lipase) was reported in a proportion of imatinib-resistant and/or intolerant Philadelphia-positive chronic myeloid leukemia patients treated with nilotinib. Acute pancreatitis was very rare, and the relevance of these laboratory alterations remains unknown. We report on 8 chronic myeloid leukemia patients who developed serum lipase/amylase elevation during treatment with nilotinib. After a median follow-up of 26 months, none of these patients developed an acute pancreatitis or clinical signs of pancreatic disease. Pancreatic hyperenzymemia never led to permanent drug discontinuation and required nilotinib temporary interruption in one case only. The median cumulative duration of dose interruptions and response to treatment were comparable in patients with or without pancreatic enzyme elevation. The mechanisms of action of nilotinib on pancreatic enzymes deserves to be investigated: however, in our experience, the relevance of pancreatic hyperenzymemia was clinically very limited.
2009
Palandri F, Castagnetti F, Soverini S, Poerio A, Gugliotta G, Luatti S, et al. (2009). Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. HAEMATOLOGICA, 94(12), 1758-1761 [10.3324/haematol.2009.010496 ].
Palandri F; Castagnetti F; Soverini S; Poerio A; Gugliotta G; Luatti S; Amabile M; Martinelli G; Rosti G; Baccarani M.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/83063
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 28
social impact